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Measuring the functional status of the tumour vasculature, including blood flow fluctuations 
and changes in oxygenation is important in cancer staging and therapy monitoring. Current 
clinically approved imaging modalities suffer long procedure times and limited spatio-temporal 
resolution. Optoacoustic tomography (OT) is an emerging clinical imaging modality that 
overcomes these challenges; by acquiring data at multiple wavelengths, OT can interrogate 
haemoglobin concentration and oxygenation directly, and resolve contributions from injected 
contrast agents. To establish the potential for OT to be used for rapid, multi-parametric, non-
invasive assessment of the tumour vasculature, we tested whether two dynamic OT 
techniques, oxygen enhanced (OE) and dynamic contrast enhanced (DCE)-OT, could provide 
surrogate biomarkers of tumour vascular function, hypoxia and necrosis. We found that 
vascular maturity leads to changes in vascular function that affect tumour perfusion, 
modulating the DCE-OT signal. Perfusion in turn regulates oxygen availability, driving the OE-
OT signal. In particular, we demonstrate for the first time a strong per-tumour and spatial 
correlation between imaging biomarkers derived from these in vivo techniques and tumour 
hypoxia quantified ex vivo. Our findings suggest that OT may in the future offer significant 
advantage for localised imaging of tumour response to vascular targeted therapies when 




Introduction: Angiogenesis, the growth of new blood vessels from surrounding host 
vasculature, can be a rate limiting process in tumour development and progression. The 
resulting tumour vasculature is often chaotic and tortuous, leading to high intra-tumoural 
heterogeneity in vascular density and function (1). A high density of tumour vasculature does 
not necessarily translate into efficient oxygen and nutrient transport (2). Diffusion-limited 
hypoxia emerges early in tumour development, as rapidly proliferating cancer cells experience 
a gradient of hypoxia with increasing distance from the nearest perfused blood vessel (3). 
Perfusion-limited (or ‘cycling’) hypoxia occurs in cells close to blood vessels that experience 
rapid spatio-temporal fluctuations in local oxygen delivery due to highly variable blood flow (4). 
Hypoxia in solid tumours has been associated with both chemo- and radio-resistance (4), as 
well as poor prognosis (5,6). Furthermore, anti-angiogenic and vascular disrupting therapies 
are under active clinical development, with highly variable rates of success (7,8). A rapid test 
to probe the functional status of the tumour vasculature, including blood flow fluctuations and 
changes in oxygenation, could therefore improve cancer patient management, for example: in 
distinguishing benign from malignant tumours; in monitoring response to chemo- and radio-
therapy; and in aiding development of novel vascular targeted therapies (1).  
Non-invasive imaging of tumour vascular function in the clinic usually requires 
administration of an exogenous untargeted contrast agent followed by longitudinal imaging of 
wash-in and wash-out kinetics, referred to as Dynamic Contrast Enhanced (DCE) imaging (9). 
DCE magnetic resonance imaging (MRI) has been broadly applied to interrogate tumour 
perfusion by tracking the dynamics of an injected Gadolinium-based small molecule contrast 
agent (10). Unfortunately, an increasing number of reports suggesting long-term toxicity of 
Gadolinium chelates (11) may limit future use and typical voxel sizes of ~2 x 2 x 4 mm3 (12) 
limit interrogation of spatial heterogeneity (5). To avoid the use of contrast agents, label-free 
MRI techniques that are sensitive to perfusion such as arterial spin labelling (ASL) may be 
used,  however, ASL can suffer from low signal-to-noise ratio, typically requiring voxel sizes 
of over ~3 x 3 x 4 mm3 in patients (13). A more established MRI technique is blood oxygen 
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level dependent (BOLD) MRI, sensitive to deoxyhaemoglobin content, which can reach sub-
milimetre in-plane spatial resolution and temporal resolution of < 10 secs clinically (14). The 
BOLD signal appears to reflect tumour perfusion and hypoxia, based on correlations with 
immunohistochemistry (15)and can be applied, for example, to indicate prognosis in chemo- 
and radio- therapy (14,16). Despite this promise, attempts to directly correlate the BOLD and 
DCE-MRI signals have shown no significant relationship(17) and it has been suggested that 
some ambiguity remains in the biological interpretation of the BOLD signal (14,18).   
Considering other clinical imaging modalities, positron emission tomography (PET) 
contrast agents are available clinically for visualisation of vascular function (e.g. H215O) and 
hypoxia (e.g. 18F-MISO). While these approaches benefit from the exquisite sensitivity of PET, 
difficulties arise from the fundamental spatial resolution limits(19) and the requirement to 
administer a radiopharmaceutical, which is a particular challenge for short-half-life agents 
such as 15O (t1/2 ~ 2 min)(20). A more cost-effective option may be possible with diffuse optical 
spectroscopic imaging, which measures concentrations of oxy- and deoxy-haemoglobin as 
surrogate markers of hypoxia and is in clinical trials (21), though this all-optical imaging 
approach suffers from very poor spatial resolution (~1 cm). A cost-effective and high-resolution 
solution could be available using DCE ultrasound with gas-filled microbubbles as an 
exogenous contrast agent(22), yet safety concerns related to injection of microbubbles have 
been raised in patients(23). Thus, there remains a need for cost-effective, non-invasive 
imaging of tumour vascular function with high spatio-temporal resolution, ideally available 
without contrast agent administration.  
 Optoacoustic Tomography (OT) is an emerging imaging modality (24) that is currently 
in clinical trials (25). OT reveals the distribution of tissue optical absorption in real time (26). 
Since the optical absorption spectra of oxy- and deoxy-haemoglobin are distinct, acquiring OT 
data at multiple wavelengths makes it possible to derive imaging biomarkers that relate to total 
haemoglobin concentration (THb) and oxygenation (SO2). These imaging biomarkers provide 
complementary haemodynamic information to those measured clinically with DCE-based 
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techniques and also the label-free MRI-based techniques introduced above. OT has been 
shown to monitor the evolution of tumour vasculature during disease development (27,28) and 
to detect response to vascular targeted therapies (29,30). OT has also been combined with 
DCE ultrasound (31,32) showing relationships between haemoglobin parameters and 
perfusion metrics. For these reasons, OT has already been deployed in clinical studies in 
breast, ovarian and prostate cancers among others, achieving localised imaging at depths of 
up to 7 cm with spatial resolution of 500 μm or better and wavelength tuning rates of up to 100 
Hz (25). Importantly, numerous clinical trials are underway world-wide, which are beginning to 
show great promise for the technology (despite the aforementioned depth limitations) for 
detecting tumour vascularisation and differentiating benign and malignant lesions, particularly 
in the breast (33–35).  
 In addition to the ‘static’ measurements of haemoglobin concentration and oxygenation 
available with existing OT, new techniques have recently emerged that directly report on 
vascular maturity and function. Inspired by clinically approved Oxygen Enhanced (OE) MRI 
methods, OE-OT(36) measures the change in haemoglobin oxygenation following a change 
in respiratory gas from air to 100% oxygen. Contrary to the static measurement of 
oxygenation, these ‘dynamic’ OE-OT biomarkers have been shown to correlate with 
histopathological analysis of tumour vascular function and substantially outperform the static 
biomarkers in terms of robustness and repeatability(36). DCE-OT is also available, using the 
clinically approved fluorescent agent Indocyanine Green (ICG) as an untargeted blood pool 
agent(37). Taking multi-wavelength OT data over time makes it possible to separate ICG 
signals from oxy- and deoxy-haemoglobin, giving the potential to extract spatially resolved 
relationships between tumour oxygenation and tumour perfusion in a clinical setting using non-
toxic, non-invasive OT imaging.  
The purpose of the present study was to evaluate the potential of OT to be used for 
rapid, multi-parametric, non-invasive assessment of tumour vascular function, hypoxia and 
necrosis. Here, we perform co-registered OE-OT and DCE-OT in two tumour models, showing 
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for the first time a quantitative spatial per-pixel correlation between OT metrics derived in vivo 
and the histopathological assessment of vascular maturity and tissue hypoxia ex vivo. 
Furthermore, we resolved the key determinants of OE-OT response in terms of oxygen 
delivery via the blood supply and oxygen demand in the tissue. Our findings suggest that OE-
OT and DCE-OT derived imaging biomarkers can be used as surrogate measures of tumour 
perfusion and hypoxia. We also note that OE-OT may provide a label-free alternative to DCE 
approaches for evaluating tumour perfusion that can be readily implemented into the imaging 
protocol of the emerging clinical optoacoustic technology thanks to its negligible toxicity risk.  
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Materials and Methods: 
Animal Experiments 
All animal procedures were conducted in accordance with project (70-8214) and 
personal licenses (IDCC385D3) issued under the United Kingdom Animals (Scientific 
Procedures) Act, 1986 and were approved locally under compliance form number CFSB0671. 
Subcutaneous tumours were established in male BALB/c nude mice (Charles River). 1.5x106 
PC3 prostate adenocarcinoma cells suspended in a mixture of 50µL phosphate buffered saline 
(PBS) and 50µL matrigel (354248, Corning) were inoculated subcutaneously in both lower 
flanks of n=9 mice (resulting in n=18 tumours). 1x106 K8484 mouse pancreatic 
adenocarcinoma cells suspended in 100 µL PBS were inoculated subcutaneously in both 
lower flanks of a further n=4 mice (resulting in n=7 tumours). The K8484 cells(38) were derived 
from a pancreatic adenocarcinoma of a transgenic mouse model(39,40) and were kindly 
donated by Prof. Duncan Jodrell’s lab at the CRUK Cambridge Institute, providing validation 
of the findings in a model of distinct morphology to the prostate tumours. Authentication of 
PC3 cells using Genemapper ID v3.2.1 (Genetica) by STR Genotyping (1/2015) showed 94% 
match. No authentication was performed in K8484 cells. Both cell types were mycoplasma 
tested by RNA-capture ELISA prior to use (PC3, 13/03/2017); K8484, 05/09/2017). Cells were 
used at 4 passages from thawing from frozen stocks. Tumour growth was monitored by 
callipers and imaging was performed when tumours reached ~8mm in any linear dimension.   
To investigate the effect of vascular disruption on the optoacoustic measurements and 
evaluate its relationship with vascular maturity, 1.5x106 PC3 prostate adenocarcinoma cells 
were inoculated as described above in a further n=8 mice (resulting in n=16 tumours). In 4 
animals both tumours could not be visualised in a single imaging slice, resulting in 4 tumours 
being excluded, leaving n=12 tumours for analysis. Combretastatin 4A Phosphate (CA4P, 
C7744, Sigma-Aldrich), a potent Vascular Disrupting Agent with well-established efficacy in 
preclinical models was used (30,41,42) . When tumours reached ~8mm linear dimension, mice 
were randomly allocated into two groups: treated (CA4P, 8 mL/kg of 12.5mg/mL solution 
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dosed intraperitoneally to achieve a dose of 100mg/kg, n=7 tumours, 4 mice), and vehicle 
(PBS 8ml/kg intraperitoneally, n=5 tumours, 4 mice).  
Optoacoustic Tomography (OT) 
A commercial multispectral optoacoustic tomography (MSOT) system (inVision 256-
TF, iThera Medical GmbH) was used for this study(43). Briefly, a tunable optical parametric 
oscillator pumped by an Nd:YAG laser provides excitation pulses with a duration of 9ns for 
wavelengths ranging from 660nm to 1300nm at a repetition rate of 10Hz, wavelength tuning 
speed of 10ms and a peak pulse energy of 90mJ at 720nm. Ten arms of a fibre bundle provide 
uniform illumination of a ring-shaped light strip of approximately 8mm width. For ultrasound 
detection, 256 toroidally focused ultrasound transducers with a centre frequency of 5MHz 
(60% bandwidth), organized in a concave array of 270 degree angular coverage and a radius 
of curvature of 4cm, are used. 
 Mice were prepared for OT according to our standard operating procedure(44). Briefly, 
mice were anaesthetised using <3% isoflurane, placed on a heat pad, and a catheter (home-
made with 30G needle) was placed in the tail vein and fixed in place using tissue glue 
(TS1050071F, TissueSeal). The mouse was subsequently moved into a custom animal holder 
(iThera Medical) wrapped in a thin polyethylene membrane, with ultrasound gel (Aquasonic 
Clear, Parker Labs) used to couple the skin to the membrane. The holder was placed within 
the imaging chamber of the MSOT system filled with degassed heavy water (617385, Sigma-
Aldrich) maintained at 36°C, with the end of the catheter line available outside of the imaging 
chamber for contrast agent injection. Heavy water was used due to other studies performed 
in parallel on the MSOT system and is not essential to the study described here since the 
optical absorption of water and heavy water is similar in the spectral range interrogated.    
Mice were allowed to stabilise their physiology for 15 minutes within the system prior 
to initialisation of the scan and their respiratory rate was then maintained in the range 70-
80bpm with ~1.8% isoflurane concentration for the entire scan. The respiration rate was 
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monitored by observing the breathing motion of the animal using a video feed from an optical 
camera positioned within the imaging chamber and counting the breaths over a minute using 
a stopwatch. We first performed Oxygen Enhanced Optoacoustic Tomography (OE-OT) (36), 
in which the breathing gas was switched manually from medical air (21% oxygen) to pure 
oxygen (100% oxygen) using separate flow meters (according to the schedule in 
Supplementary Figure S1). A single slice was chosen for imaging showing the largest cross-
sectional area of the tumours on both flanks where possible. Images were acquired in the 
single slice using 10 wavelengths (700, 730, 750, 760, 770, 800, 820, 840, 850, 880 nm) and 
an average of 6 pulses per wavelength; an entire single slice multi-wavelength data acquisition 
was 5.5s in duration. In the CA4P and vehicle treated mice, where imaging was performed 
twice, the imaging slice in the second session was chosen to be as close as possible to the 
first one by visual alignment to the reconstructed images of the first scan. 
Following OE-OT, the breathing gas was switched back to medical air and after 10 
minutes allowed for equilibration, the Dynamic Contrast Enhanced (DCE) OT was initiated in 
the same imaging slice. Images were acquired using 5 wavelengths (700, 730, 760, 800, 850 
nm) and an average of 10 pulses. After 1 minute of continuous imaging to establish the 
baseline signal, a bolus of Indocyanine Green (ICG, 40nmol/20g mouse in PBS)(45) was 
injected intravenously through the catheter, followed by a pulse of PBS to flush the line. OT 
was continued for a further 15 minutes to sample the enhancement curve.  
All mice underwent the full OT procedure at least once. Mice receiving CA4P or vehicle 
were imaged at 48h before treatment to ensure clearing of the injected contrast agent and 
then again at 4h after treatment.  
Histopathologic Tumour Staining 
Following the last OT procedure, mice were immediately sacrificed by cervical dislocation 
while still under anaesthesia. The tumours were then excised, taking care for the orientation 
to be preserved, and cut in half along the imaging plane. The top and left hand side of the 
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tumours were marked with green and red tissue marking dyes (RCD-0727-3, RCD-0727-5, 
Cell Path) to later indicate the orientation of histopathologic sections relative to the in vivo 
imaging procedure. One half was then fixed in neutral buffered 10% formalin for 24h prior to 
paraffin embedding. Fixed blocks were sectioned at 3µm thickness at 4 separate levels within 
the tumour spaced by 500µm apart. Haematoxylin and eosin (H&E) staining and 
immunohistochemistry were performed. Adjacent sections from each of the 4 levels were 
stained with: CD31 (anti-mouse, BD Biosciences, 553370) to indicate vessel density; alpha 
smooth muscle actin (ASMA) (anti-mouse, Abcam, ab5694) to indicate smooth muscle 
coverage; and CAIX (anti-human, BioScience Slovakia, AB1001) to indicate hypoxic regions. 
We also performed pimonidazole staining for hypoxia in a representative tumour to 
qualitatively assess the reliability of CAIX staining for hypoxia visualisation in the PC3 model. 
60mg/kg pimonidazole hydrochloride (Hypoxyprobe) in PBS was injected intraperitoneally 60 
minutes before sacrifice. IHC staining (Mab-1 antibody, 4.3.11.3, Hypoxyprobe) was 
performed on the sections. Spatial co-localisation between CAIX and pimonidazole staining 
was observed (Supplementary Figure S2). All immunostainings were performed with DAB as 
substrate. All sections were digitized at 20x with an Ariol System (Aperio Technologies Ltd).  
Optoacoustic Tomography Image Analysis 
All OT analysis was performed in MATLAB 2017b (Mathworks) using custom software. 
OT images were reconstructed using an acoustic backprojection algorithm (iThera Medical) 
with an electrical impulse response correction, to account for the frequency dependent 
sensitivity profile of the transducers(46), and a speed-of-sound adjustment, to focus the 
images. Images were reconstructed with a pixel size of 75μm x 75μm, which is approximately 
equal to half of the in-plane resolution of the InVision 256-TF, to facilitate region drawing. It 
should be noted that the out-of-plane resolution of this system is approximately 0.9mm (47). 
Regions of Interest (ROIs) were drawn manually around the tumour area (excluding the skin) 
and a healthy, well vascularised tissue region around the spine, in the 800nm (isosbestic) 
 12 
image taken from the first frame of the OE-OT scan. The reconstructed images were 
downsampled to 200μm x 200μm pixel size for further analysis, to improve response 
classification, as described below. 
For OE-OT analysis, a pseudoinverse matrix inversion (pinv function in MATLAB 
2017b) was used for spectral unmixing of the relative weights of oxy- [HbO2] and deoxy-
haemoglobin [Hb] independently in each pixel. Since OT is not able to accurately measure the 
absolute SO2 without the precise knowledge of optical energy distribution, we denote the 
approximate oxygenation metric derived in this study as the apparent SO2MSOT rather than 
absolute SO2. SO2MSOT was computed as the ratio of HbO2 to total haemoglobin 
THb=[HbO2+Hb]. Average SO2MSOT was calculated in each pixel for air and oxygen breathing 
periods and denoted SO2MSOT (Air) and SO2MSOT (O2) respectively. The amplitude of response 
to the oxygen gas ΔSO2MSOT=SO2MSOT (O2) - SO2MSOT (Air) was calculated for each pixel 
(illustrated in Figure 1A). The variability of the signal was also assessed by calculating the 
standard deviation SDOE of the SO2MSOT values between the individual scans acquired during 
air breathing. Each pixel was classified as responding to the oxygen challenge if ΔSO2MSOT 
exceeded 2 x SDOE (see Supplementary Figure S3). A small fraction of pixels showed 
artefactual negative Hb or HbO2 levels due to low signal and were classified as non-
responding. The OE Responding Fraction (OE RF) was subsequently calculated for each 
tumour and scan as the ratio of the number of tumour pixels classified as responding to the 
total number of pixels in the tumour ROI. 
DCE-OT analysis was performed similarly. The same ROIs as for the corresponding 
OE-OT scans were used, since the imaging was performed in the same slice and the 
movement of the anaesthetised animal between the scans was negligible. After down-
sampling the reconstructed image, linear spectral unmixing as above was performed for HbO2, 
Hb and ICG. The amplitude of ICG enhancement, ΔICG, was quantified as the difference 
between the average baseline ICG signal and the maximum signal recorded in the first 3 
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minutes after injection (illustrated Figure 1A) to capture the perfusion rather than accumulation 
effect of the dye. Variability of the ICG signal was also measured as the standard deviation of 
the individual images acquired before contrast agent injection (SDDCE). Each pixel was then 
classified as enhancing when ΔICG exceeded 2 x SDDCE (see Supplementary Figure S3) with 
artefactual, negative pixels classified as non-enhancing. DCE Responding Fraction (DCE RF) 
was computed accordingly for each tumour.  
Correlations between OE and DCE signals were calculated for each tumour on a per-pixel 
basis. The results presented are from all mice (n=12+18 tumours). The small fraction of pixels 
showing artefactual SO2MSOT or ICG signal values were excluded from the correlation analysis. 
Spearman rank correlation coefficient was calculated (MATLAB) and quoted, due to the 
apparent non-linear monotonic relationship between the metrics.  
Histopathologic Image Analysis and Data Co-registration  
For each tumour, 4 sections were analysed (see ‘Histopathologic Tumour Staining’). 
Necrosis was identified from H&E sections using a Convolution Neural Network (CNN) 
approach. The schematic of the CNN layer architecture is presented in Supplementary Figure 
S4. The viable and necrotic patches of H&E sections for training the model were identified 
manually. A threshold of 0.5 was applied to the necrosis score maps to discriminate the 
necrotic from viable regions as the probabilistic output had a range from 0 to 1, meaning that 
values below or above 0.5 have a higher likelihood of being viable or necrotic tissue 
respectively. The necrotic fraction was quantified as the ratio of the total necrotic area to total 
tumour area across a whole section. Model performance was assessed by qualitative 
comparison to H&E sections, an example of which is demonstrated in Supplementary Figure 
S5, and quantitative comparison to results of manual segmentation, performed in Imagescope 
(Aperio Technologies Ltd). A strong, significant correlation was observed between the model 
and manual quantification (r=0.75, p<0.0001, see Supplementary Figure S6).  
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Haemorrhagic areas were identified in H&E sections based on their colour. 
Quantification of haemorrhagic fraction was performed automatically using Halo (Indica Labs) 
image analysis software. Analysis of CD31 and ASMA coverage was also performed using 
Halo software, quantifying the CD31 positive area (to measure the amount of vasculature), as 
well as the CD31 positive areas that were also positive for ASMA in adjacent sections to 
identify mature vasculature with smooth muscle coverage(2). The fraction of area positive for 
both CD31 and ASMA to the CD31 positive area was quoted as a metric. CAIX analysis was 
performed using custom code written in MATLAB. The areas of CAIX positive staining were 
identified based on colour deconvolution(48) of the antibody, cell nuclei and background. The 
correct colours for the 3 classes were computed by manually outlining example areas in two 
sections. CD31/ASMA analysis was performed in the CA4P/vehicle treated cohort (n=12), to 
increase the vascular maturity range probed. The CAIX and necrosis analysis was performed 
in the other cohort only (n=18), as the different experimental protocol (2 imaging sessions for 
CA4P cohort, 1 for untreated cohort) made the histology datasets not eligible to be combined. 
To evaluate the relationship between OT metrics of vascular function and 
histopathologic assessment of tissue hypoxia, point set registration was performed with points 
determined by the applied tissue marking dyes(49).  
The ΔSO2MSOT and ΔICG OT images were then compared spatially to CAIX sections. 
Kernel density estimation, assuming a bimodal intensity distribution with low and high values, 
was applied on pooled CAIX stain intensity values across all tumours to obtain a discriminative 
threshold for binarisation of stain intensity in individual sections. The binarised CAIX and 
necrosis maps were overlaid, and the necrotic areas were excluded from the analysis. Mean 
ΔSO2MSOT and ΔICG values in CAIX positive and negative viable regions were then calculated. 
The differences between the ΔSO2MSOT and ΔICG values in the CAIX positive and negative 
regions were then extracted for each tumour, with a value significantly different from 0 taken 
as a measure of differential response. This informed on spatial co-localisation and co-
occurrence of high/low ΔSO2MSOT with negative/positive CAIX regions. It should be noted that 
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this approach to image co-registration is subject to human error in tissue handling and 
sectioning, which leads to a high rate of exclusion for the analysis. Out of the 18 tumours 
analysed in the cohort, 8 had to be excluded due to failure of the registration, arising from 
distorted or torn tissue sections, resulting in misplaced tissue marking dyes, which in turn 
obstructed accurate registration of the image pairs. 
Statistical Analysis 
All errors are quoted as the standard error on the mean unless otherwise stated. All 
statistical analyses were performed in OriginPro 9 (OriginLab). Paired two-tailed t-test 
compared different metrics in each tumour and changes in parameters due to CA4P treatment; 
unpaired two-tailed t-test assuming equal variances compared between cohorts. One-tailed t-
test was used to assess whether the differences in OT parameters between low and high CAIX 
staining regions are significantly above 0 for the co-registered histopathology and OT image 
analysis. Only the last scan immediately before sacrifice was used for correlations with 
histology, and Pearson rank test was performed to assess the significance. p<0.05 was 




Oxygen Enhanced (OE) and Dynamic Contrast Enhanced (DCE) OT responses are 
strongly correlated. 
Using our intrinsically co-registered OE-OT and DCE-OT data, we first sought to 
examine the spatial correlations between the tumour OE and DCE responses. The amplitudes 
of these responses, ΔSO2MSOT (Figure 1A, C) and ΔICG (Figure 1B, D) respectively, were 
compared on a per-pixel basis. Highly significant correlations (p value <10-6 in all cases) were 
observed between these two metrics (Figure 1E). The correlation deviates from linearity for 
the extreme values, suggesting Spearman rank correlation coefficient as a more informative 
estimate of the relationship (Figure 1E). While very strong correlations between OE and DCE 
response were observed in both tumour cohorts (Spearman r=0.64±0.02, n=30 PC3 tumours; 
Spearman r=0.65±0.07, n=7 K8484 tumours), no correlation was observed to the static metrics 
of SO2MSOT(Air) or SO2MSOT(O2) measured at baseline, indicating that these metrics are not 
sensitive to tumour perfusion (Spearman r=-0.16±0.05 and r=-0.11±0.05 for SO2MSOT (Air) and 
SO2MSOT (O2) respectively for PC3, n=30 PC3 tumours, r=-0.04±0.09 and r=0.25±0.09 
respectively for K8484). The correlations for all tumours analysed are summarised in Figure 
1F. 
ICG retaining pixels in DCE-OT show weak or no OE-OT response. 
Examining the DCE-OT data in greater depth, it was clear that two classes of pixels 
showing distinct ICG kinetics were present. The first such group, referred to as ‘clearing’ 
consistently showed an obvious enhancement peak followed by exponential clearance of the 
contrast down to a plateau (Figure 2A and 2B, blue). The second such group, referred to as 
‘retaining’ showed an enhancement after injection, but displayed no clearance; the level of 
signal either remained high and stable over the duration of the experiment, or even increased 
gradually (Figure 2A and 2B, red). As might be expected based on established differences in 
vascular maturity(36), clearing regions tended to be more prevalent in the rim than the core of 
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the tumour, with the fraction of the rim occupied by clearing pixels being significantly higher 
than the corresponding fraction of the core (0.51±0.04 vs. 0.39±0.05, p=0.002, n=30 PC3 
tumours. 0.44±0.13 vs. 0.16±0.06, p=0.01, n=7 K8484 tumours).  
 Interestingly, the OE-OT responses of these two distinct classes of DCE response also 
showed significant differences (Figure 2C). Retaining regions demonstrate weaker OE 
response (Figure 2D) and have a significantly lower OE Responding Fraction than Clearing 
regions (0.55±0.05 vs. 0.25±0.02, p<10-5, n=30 PC3 tumours). The retaining regions also 
show a weaker correlation between the ΔSO2MSOT and ΔICG (Figure 2E) than the clearing 
regions (0.57±0.03 vs. 0.44±0.04, p=0.007).  
Tumour DCE-OT signal is driven predominantly by vascular maturity while OE-OT is 
also strongly related to hypoxia and necrosis. 
The relationships observed between OE-OT and DCE-OT suggested that similar 
vascular characteristics may underpin their responses. We next broadly explored the 
correlations between the in vivo OT responses and the ex vivo histopathological analysis 
relating to vascular maturity (ASMA coverage of CD31 positive blood vessels), hypoxia (CAIX 
positivity) and tumour viability (necrosis assessed with H&E) on a per-tumour basis in PC3 
tumours, where our study was sufficiently well powered to identify significant correlations. 
Vascular maturity (Figure 3A) showed a significant positive correlation with both OE 
Responding Fraction (OE RF, r=0.58, p=0.048, n=12 PC3 tumours) and DCE Responding 
Fraction (DCE RF, r=0.78, p=0.002, n=12 PC3 tumours) (Figure 3B, C). As could be expected 
given the direct influence of vascular maturity on vessel function and subsequently on 
perfusion, a higher and more significant correlation was observed for DCE RF than for OE RF.  
A significant negative correlation was found between hypoxia (based on CAIX positive 
area fraction) and OE RF (Figure 4A, Supplementary Figure S7; r=-0.68, p=0.002, n=18 PC3 
tumours). The negative correlation between hypoxia and DCE RF was weaker (Figure 4A, 
Supplementary Figure S7; r=-0.49, p=0.04, n=18 tumours). A negative correlation was also 
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observed between OE RF and the tumour necrotic fraction (Figure 4B, Supplementary Figure 
S8; r=-0.56, p=0.016, n=18 tumours), however, no significant relationship was seen for DCE 
RF (Figure 4B, Supplementary Figure S8; r=-0.42, p=0.08, n=18 tumours).  
Given the strong relationship between hypoxia and OE-OT response, we investigated 
further by examining the spatial co-localisation of high ΔSO2MSOT and low CAIX signals. Taking 
each CAIX stained section (Figure 5A) and H&E stained section (Figure 5B), we performed 
an image co-registration and down-sampled the spatial resolution of the CAIX image 
(binarised into high and low staining regions) to match that of the in vivo OT image (Figure 
5C). The resulting co-registered CAIX data was then compared to ΔICG (Figure 5D) and 
ΔSO2MSOT (Figure 5E) on a per-pixel basis. Where successful co-registration was possible 
(n=10 PC3 tumours, see Methods), the analysis revealed that areas of low CAIX staining 
(considered to reflect low tissue hypoxia) were associated with a notably higher mean 
ΔSO2MSOT level than the areas of high CAIX staining (Figure 5E). The difference between 
average ΔSO2MSOT taken in low CAIX compared to that in high CAIX regions was significantly 
higher than 0 when compared across all tumours (difference=0.014±0.005 vs. 0, p=0.007, 
n=10 PC3 tumours). The average ΔICG was also significantly higher in normoxic than in 
hypoxic tumour regions in line with the per-tumour findings (difference=0.42±0.17 vs. 0, 
p=0.018, n=10 PC3 tumours). 
OE-OT and DCE-OT are highly sensitive to treatment with a vascular disrupting agent 
 Having established relationships between OE-OT and DCE-OT imaging biomarkers 
with vascular function, hypoxia, and necrosis, we then sought to evaluate their utility in 
detecting response to a vascular disrupting agent. Imaging studies were performed both 
before and 4h after administration of the vascular disrupting agent Combretastatin A4 
Phosphate. The 4h time point was chosen so as to observe the induced vascular disruption 
prior to the development of substantial tumour necrosis (30). 
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The dramatic effect of the treatment on tumour vasculature was confirmed 
histologically (Supplementary Figure S9). As desired, this was not followed by induction of 
significant necrosis in the treated tumours (necrotic fraction=0.28±0.09, n=6 vs. 0.18±0.06, 
n=5 treated vs. vehicle, p=0.38). The induced vascular disruption was qualitatively observed 
in maps of ΔSO2MSOT and ΔICG (Supplementary Figure S10A) as well as in the quantification 
of the kinetic responses in both cases (Supplementary Figure S10B,C). As expected, treated 
tumours were dominated by ICG retaining areas (as defined in Fig. 2). Clear changes in the 
spatial distribution of responding pixels could be observed in both OE-OT and DCE-OT images 
in drug treated tumours (Figure 6A), but not in the vehicle treated ones (Supplementary Figure 
S11). These changes were reflected in the responding fractions in vehicle and CA4P treated 
tumours (Figure 6B). OE RF showed a significant decrease between 48h before and 4h after 
treatment (0.47±0.05 vs. 0.16±0.03, p=0.0005, n=7 PC3 tumours). No significant change was 
seen in vehicle treated control animals (0.38±0.06 vs. 0.30±0.05, p=0.44, n=5 PC3 tumours). 
Similarly, DCE RF showed a significant decrease (0.63±0.05 vs. 0.32±0.02, p=0.0001, n=7 




The balance of oxygen supply and demand in solid tumours can be a key determinant of 
prognosis and response to therapy. The aim of this work was to evaluate the potential of imaging 
biomarkers accessible using OT to be used in rapid, multi-parametric and non-invasive 
assessment of tumour vascular function and monitoring response to therapy. 
We first examined the relationship between the two OT imaging biomarkers under study: 
ΔSO2MSOT, accessible without the introduction of a contrast agent using OE-OT; and ΔICG, 
requiring administration of the clinically approved and non-toxic contrast agent indocyanine green 
and imaged through a DCE-OT technique. These dynamic biomarkers were strongly spatially 
correlated in both tumour models examined, suggesting that perfusion is a strong determinant of 
response in both techniques. The kinetics of the DCE-OT response also showed strong 
differences between ‘clearing’ and ‘retaining’ regions, the latter of which have been previously 
described as associated with the enhanced permeability and retention effect in areas of immature 
and leaky vasculature(50,51). These regions also showed distinct OE-OT responses, with greater 
ΔSO2MSOT seen in clearing regions. 
We then established how these OT imaging biomarkers were connected with ex vivo 
measurements of vascular function, as well as tumour hypoxia and necrosis; these relationships 
are summarised in Figure 7. Vascular maturity leads to changes in vascular function that affect 
tumour perfusion, modulating the DCE-OT signal. Perfusion in turn regulates oxygen availability, 
driving the OE-OT signal. Insufficient oxygen supply leads to tissue hypoxia and eventually 
necrosis (4) (Figure 7, bottom row). These relationships, and hence our understanding of the OE 
and DCE-OT signals, were directly confirmed by the correlations observed between our in vivo 
OT and ex vivo histopathological measurements (Figure 7, middle row). The strength of the 
correlation reflected how closely the individual measurement is linked with the underlying 
physiological process (Figure 7, top row), overall revealing a complex, yet consistent network of 
relationships in the tumour vascular microenvironment. These findings indicate that the response 
for DCE-OT is driven most strongly by perfusion and vascular function, which would be expected 
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given that ICG shows strong serum binding in vivo. The response for OE-OT appears to also be 
governed strongly by perfusion and vascular function but is further modulated by the tumour 
oxygen demand. The strong and significant relationships observed between the OE responding 
fraction and hypoxia area on a per-tumour basis were also confirmed on a spatial per-pixel basis.  
Treatment with a potent vascular disrupting agent, Combretastatin A4 Phosphate, was 
used to induce vascular shutdown, causing a dramatic perfusion drop, resulting in a significant 
decrease in DCE RF, as expected. Interestingly, the OE RF showed equally high sensitivity to the 
vascular shutdown, indicating that it could be used as an alternative to the contrast agent-based 
DCE methods for detecting response to vascular targeted therapies. Both of our surrogate 
biomarkers were able to sensitively detect response to the vascular targeted therapy. 
In line with our previous findings(36), static OT biomarkers such as SO2MSOT(O2) and 
SO2MSOT(Air) showed little relationship to perfusion or hypoxia. Similar relationships were 
examined previously comparing tumour oxygenation assessed using static OT with DCE 
ultrasound(31,32) or pimonidazole staining(52).  While some spatial relationships were noted, 
particularly in relation to the necrotic tumour core, these studies were limited respectively by a lack 
of histological validation, poor sensitivity of the optoacoustic imaging approach applied and small 
numbers of biological replicates. 
 There remain some limitations to the presented work that must be addressed in future 
studies. From a biological perspective, vascularisation of subcutaneous models differs from 
that of orthotopic xenografts and spontaneous tumours(53) and may not be entirely 
representative of the vascular function found clinically in solid tumours. These findings should 
therefore be validated in orthotopic and transgenic tumour models prior to application of 
dynamic OT metrics in studies of cancer biology or in the clinic. In our subcutaneous PC3 
model, good co-localisation was observed between CAIX and pimonidazole staining, which 
we took as an indication that CAIX staining indeed reflected hypoxia in this model. While CAIX 
staining is well-documented to be regulated by the activation of Hypoxia Inducible Factor (HIF-
1)(54) and has been widely used for ex vivo hypoxia identification, non-specific effects can be 
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observed in some models, therefore if our findings are to be further validated in other tumour 
models, it would be prudent to use multiple methods to assess hypoxia ex vivo.  
Some further limitations exist in the efficient clinical translation of OT and associated 
imaging biomarkers. Penetration depths of up to 3-7cm (25) have been reported in patients, 
enabling access to superficial cancer sites, such as those in the breast or head and neck. With 
the ongoing development of endoscopic probes, imaging organs such as the prostate (55) is 
also expected to be possible, yet access to some deep seated organs will remain limited even 
with these technological advances. The localised nature of OT means that it would be most 
appropriately placed in the patient management pathway after diagnosis or identification of a 
suspicious lesion using another imaging technique. Light attenuation at depth in tissue poses 
an additional challenge for signal quantification. Methods available to perform light fluence 
correction of OT data have received only limited validation in vivo (47). Future work is required 
to directly relate OT data to absorbed optical energy density and enable absolute quantification 
if desired. However, qualitative features derived from clinical optoacoustic images have also 
shown significant prognostic value (56). 
In summary, we have shown that non-invasive and non-toxic OE-OT and DCE-OT 
techniques can be used to interrogate tumour vascular function, hypoxia and necrosis. The 
comprehensive histopathological validation of the OT imaging biomarkers presented here 
indicates that despite the aforementioned technical challenges that face the technology, OT 
is capable of providing a unique and rapid insight into the tumour vascular microenvironment. 
While DCE-OT requires administration of a contrast agent, OE-OT provides a completely non-
invasive, label-free measurement; our findings indicate that the oxygen challenge approach 
could be used as a safe alternative for exogenous contrast injection as it has been used 
clinically with no associated risk(57). OT is already being tested, with promising results in 
numerous clinical trials in cancer patients(33–35), despite some technical limitations of the 
technology. In the future, the low cost, portability and simplicity of OT may offer significant 
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advantage for localised imaging of tumour response to vascular targeted therapies when 
compared to existing clinical DCE methods, particularly in the neo-adjuvant setting. 
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Figures with legends: 
Figure 1. Tumour oxygen enhanced optoacoustic tomography (OE-OT) and dynamic 
contrast enhanced (DCE)-OT responses are strongly correlated. A strong spatial 
relationship was observed between the response maps for OE-OT (A) and DCE-OT (B) in 
both PC3 (top) and K8484 (bottom) tumours. OE and DCE kinetic curves (C,D) were used to 
quantify metrics as denoted that were then compared in correlation analyses on a per-pixel 
basis in each tumour. (E) Exemplar per-pixel correlations for each tumour type. (F) When 
comparing correlations extracted from the entire tumour cohort (each data point represents 
one tumour), significantly stronger correlations were observed to the dynamic OE-OT metric 
ΔSO2MSOT than either static metrics of SO2MSOT (Air) and SO2MSOT(O2). No correlation 
(correlation coefficient of 0) is indicated with a red dashed horizontal line. Data in (A-E) are 
exemplars taken from one representative tumour for each type. Data in (F) are taken from the 
entire tumour cohort (n=30 PC3, n=7 K8484). *** p<0.001 by paired two-tailed t-test. Boxes 





Figure 2. Two distinct classes of DCE kinetics also possess different OE kinetics. 
Spatially distinct regions were segmented showing ICG clearance or retention (A) following 
injection, according to the DCE-OT response kinetics (B). The retaining regions show little or 
no OE-OT response (C), reflecting the poorer vascular function in the area. Response maps 
of OE-OT (D) and DCE-OT (E) are also shown, with the Clearing, Retaining and non-
enhancing regions denoted in light blue, red and black regions of interest respectively. These  
further indicate that the strongest OE response occurs in Clearing regions, as suggested in 





Figure 3. OE-OT and DCE-OT responses show a significant positive correlation with 
vascular maturity. (A) Overlaid CD31 and ASMA stained sections were used to evaluate the 
fraction of blood vessels positive for ASMA (red on CD31 stained section). The OE 
Responding Fraction (B) and DCE Responding Fraction (C) both show a significant correlation 
to tumour vascular maturity (B), with DCE showing a stronger relationship. The analysis 
includes tumours treated with Combretastatin-A4-Phosphate (red points, n=7 PC3 tumours), 
which show clearly lower ASMA coverage than vehicle treated tumours (black points, n=5 PC3 
tumours). * p<0.05, ** p<0.01 shows the strength of the correlation assessed using a Pearson 











Figure 4. OE-OT is also strongly related to tumour hypoxia and necrosis. (A) 
Representative CAIX stained sections were used to quantify the extent of tumour hypoxia, to 
which OE-OT response shows a strong inverse correlation, while the DCE-OT response 
shows a weaker relationship. (B) H&E stained sections were used to quantify the extent of 
tumour necrosis (green line outlines necrotic area), to which OE-OT again showed a strong 
inverse correlation, while DCE-OT response was not significant. Analysis shown from n=18 
PC3 tumours. n.s. not significant, * p<0.05, ** p<0.01. Line of best fit with 95% confidence 




Figure 5. Spatial co-registration allows comparison of OE-OT and DCE-OT response in 
hypoxic tumour tissue. CAIX stained sections (A) were binarised into low and high stain 
areas. This information was overlaid with necrosis map obtained from H&E sections (B) then 
co-registered and down-sampled (C) for comparison with the optoacoustic images. DCE-OT 
ΔICG (D) and OE-OT ΔSO2MSOT (E) could then be compared to the degree of CAIX staining in 
viable areas. The box plots show that for the analysed tumours the difference between ΔICG 
(D) and ΔSO2MSOT (E) between areas of low and high CAIX hypoxia staining, is significantly 
higher than 0 (indicated with red dashed line). Images in (A-C) from a representative PC3 
tumour. Analysis in (D,E) presented from n=10 PC3 tumours. * p<0.05, ** p<0.01 by one-tailed 





Figure 6. OE and DCE enhancement show similarly high sensitivity in detecting changes 
in vascular function. Both OE Responding Fraction and DCE Responding fraction show a 
drastic drop due to vascular shutdown caused by the treatment, as seen in representative 
enhancement maps from a PC3 tumour (A) and in box plot (n=7 treated, n=5 vehicle PC3 
tumours). n.s. not significant, *** p<0.001 by paired two-tailed t-test. Box between 25th and 






Figure 7. Summary of the relationships governing tumour physiology that have been 
established with Optoacoustic Tomography imaging biomarkers. The physiological 
relationships underpin the correlations that we observed between the in vivo and ex vivo 
measurements of physiological processes. As indicated with the colour bar, the more 
disconnected the physiological parameters are from each other, the weaker the observed 
correlations. * p<0.05, ** p<0.01. 
 
 
